RJFSA
MRNA icon

Raymond James Financial Services Advisors’s Moderna MRNA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.63M Buy
84,193
+7,262
+9% +$667K 0.01% 1158
2024
Q2 		$9.14M Buy
76,931
+10,259
+15% +$1.3M 0.01% 867
2024
Q1 		$7.1M Buy
66,672
+8,334
+14% +$840K 0.01% 959
2023
Q4 		$5.8M Buy
58,338
+1,554
+3% +$131K 0.01% 1002
2023
Q3 		$5.87M Sell
56,784
-5,672
-9% -$633K 0.01% 937
2023
Q2 		$7.59M Buy
62,456
+9,001
+17% +$1.2M 0.01% 824
2023
Q1 		$8.21M Buy
53,455
+9,386
+21% +$1.55M 0.02% 776
2022
Q4 		$7.92M Sell
44,069
-111
-0.3% -$18.1K 0.02% 753
2022
Q3 		$5.22M Sell
44,180
-1,550
-3% -$235K 0.01% 894
2022
Q2 		$6.53M Sell
45,730
-37,228
-45% -$5.32M 0.01% 806
2022
Q1 		$14.3M Buy
82,958
+2,181
+3% +$367K 0.03% 553
2021
Q4 		$20.5M Sell
80,777
-29,660
-27% -$8.67M 0.04% 448
2021
Q3 		$42.5M Sell
110,437
-10,105
-8% -$3.73M 0.09% 241
2021
Q2 		$28.3M Buy
120,542
+43,594
+57% +$7.79M 0.06% 330
2021
Q1 		$10.1M Buy
76,948
+14,044
+22% +$2.04M 0.02% 622
2020
Q4 		$6.57M Sell
62,904
-26,192
-29% -$2.65M 0.02% 719
2020
Q3 		$6.3M Sell
89,096
-650
-0.7% -$45.3K 0.02% 672
2020
Q2 		$5.76M Buy
89,746
+29,227
+48% +$1.6M 0.02% 649
2020
Q1 		$1.81M Buy
60,519
+26,569
+78% +$611K 0.01% 926
2019
Q4 		$664K Buy
33,950
+3,610
+12% +$64K ﹤0.01% 1791
2019
Q3 		$483K Buy
30,340
+15,803
+109% +$233K ﹤0.01% 1923
2019
Q2 		$213K Buy
+14,537
New +$312K ﹤0.01% 2500

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raymond James Financial Services Advisors's MRNA Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Moderna (MRNA) stake by 9.4% in Q3 2024, buying an estimated $667K and bringing the position to 84,193 shares worth $5.63M. The position accounts for 0.01% of the portfolio, ranked #1158.

Raymond James Financial Services Advisors first reported a position in MRNA in Q2 2019 and has held it in 22 quarters since. The position peaked at $42.5M in Q3 2021. 789 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Raymond James Financial Services Advisors held 84,193 shares of Moderna worth $5.63M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 7,262 Moderna shares in Q3 2024, an estimated $667K.
  • Moderna made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1158 holding.
  • Raymond James Financial Services Advisors first reported a position in Moderna in Q2 2019 and has held it in 22 quarters since.
  • Raymond James Financial Services Advisors's Moderna position peaked at $42.5M in Q3 2021.
  • 789 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.